Compare WWR & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WWR | XBIT |
|---|---|---|
| Founded | 1977 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Pharmaceuticals and Biotechnology |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8M | 66.8M |
| IPO Year | 2006 | 2015 |
| Metric | WWR | XBIT |
|---|---|---|
| Price | $0.52 | $2.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $1.92 | N/A |
| AVG Volume (30 Days) | ★ 686.5K | 44.1K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.38 | $2.09 |
| 52 Week High | $3.75 | $3.44 |
| Indicator | WWR | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 43.84 | 41.45 |
| Support Level | $0.48 | $2.16 |
| Resistance Level | $0.62 | $2.48 |
| Average True Range (ATR) | 0.03 | 0.04 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 19.40 | 33.33 |
Westwater Resources Inc is an energy technology company focused on developing battery-grade natural graphite materials through a vertically integrated, mine-to-market strategy anchored by its two primary projects in Coosa County, Alabama: the Kellyton Graphite Plant and the Coosa Graphite Deposit. Westwater also holds mineral rights to explore and mine the Coosa Graphite Deposit, which Westwater anticipates will eventually provide natural graphite flake concentrate as feedstock to the Kellyton Graphite Plant.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.